Cadrenal Therapeutics Inc (Nasdaq: CVKD), a Florida-based biopharmaceutical company, announced on Tuesday that it has received Orphan Drug Designation (ODD) from the United States Food and Drug Administration (FDA) for its tecarfarin, intended for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist device (LVAD), right ventricular assist device (RVAD), collectively known as ventricular assist devices (VADs), biventricular assist device, and total artificial heart).
The FDA's ODD program provides incentives to sponsor organisations for the development of innovative treatments for rare diseases that impact fewer than 200,000 people in the United States.
Quang Pham, Cadrenal Therapeutics' founder, chairman and chief executive officer, said: "This second orphan drug designation highlights the expanded need for tecarfarin where existing anticoagulation therapies are inadequate. We are dedicated to advancing tecarfarin through clinical development options as swiftly as possible."
ColdVentures partners with Medco Sports Medicine to combat heat stroke
Median Technologies secures funding for eyonis Lung Cancer Screening software
MicroAire Surgical Instruments acquires NEOSYAD
UCB launches 320 mg/2 mL single-injection administration option for BIMZELX (bimekizumab-bkzx) in US
Concept Medical reports first patient enrolled in MagicTouch SCB trial in peripheral artery disease
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Revvity and Element Biosciences partner to enhance neonatal sequencing for IVD testing
Implantica publishes real-world data supporting RefluxStop efficacy
Abingdon Health subsidiary awarded GBP500,000 contract
NanoVibronix completes pilot phase of UroShield study at University of Michigan
Hologic acquires Gynesonics for USD350m
Inogen secures FDA clearance for SIMEOX 200 Airway Clearance Device
Microtech commences human clinical trial of microsensor platform for heart failure
Humacyte Global receives approval from FDA for Symvess
Defense Diagnostics launches DEFENT ONE All-In-One Fentanyl Detection Device in US